These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 35915937

  • 1. [Expression and clinical significance of COL1A1 and COL1A2 genes in malignant pleural mesothelioma tissues].
    Li B, Pu YQ, Li ZL, Zhao Y, Zi JJ, Xiong W.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Jul 20; 40(7):487-494. PubMed ID: 35915937
    [Abstract] [Full Text] [Related]

  • 2. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
    Li B, Zhou CX, Pu YQ, Qiu L, Mei W, Xiong W.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar 20; 41(3):168-176. PubMed ID: 37006141
    [Abstract] [Full Text] [Related]

  • 3. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
    Mei W, Wang XM, Liu RA, Xiong W, Zhang YP.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr 20; 42(4):258-267. PubMed ID: 38677988
    [Abstract] [Full Text] [Related]

  • 4. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K, Hiroshima K, Nagashima Y, Nakazawa T, Ogihara A, Orimo M, Sato Y, Katsura H, Kanzaki M, Kondo M, Tagaya E.
    BMC Cancer; 2023 Dec 07; 23(1):1206. PubMed ID: 38062416
    [Abstract] [Full Text] [Related]

  • 5. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma].
    Wang N, Zhao QN, Yuan Q, Zhu BL, Wu W.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep 20; 41(9):641-647. PubMed ID: 37805421
    [Abstract] [Full Text] [Related]

  • 6. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M, Yu M, Zhu LJ, Yuan XY, Zhang X.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb 20; 39(2):91-98. PubMed ID: 33691361
    [Abstract] [Full Text] [Related]

  • 7. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, Maki Y, Tanaka N, Shien K, Furukawa M, Yamamoto H, Asano H, Tsukuda K, Kishimoto T, Otsuki T, Miyoshi S.
    Lung Cancer; 2013 Dec 20; 82(3):485-90. PubMed ID: 24168922
    [Abstract] [Full Text] [Related]

  • 8. COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma.
    Zhang C, Liu S, Wang X, Liu H, Zhou X, Liu H.
    Biomed Res Int; 2021 Dec 20; 2021():5320941. PubMed ID: 33490271
    [Abstract] [Full Text] [Related]

  • 9. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
    Qualiotto AN, Baldavira CM, Balancin M, Ab'Saber A, Takagaki T, Capelozzi VL.
    Front Immunol; 2023 Dec 20; 14():1268927. PubMed ID: 37901248
    [Abstract] [Full Text] [Related]

  • 10. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
    Zauderer MG, Martin A, Egger J, Rizvi H, Offin M, Rimner A, Adusumilli PS, Rusch VW, Kris MG, Sauter JL, Ladanyi M, Shen R.
    Lancet Digit Health; 2021 Sep 20; 3(9):e565-e576. PubMed ID: 34332931
    [Abstract] [Full Text] [Related]

  • 11. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D.
    Clin Cancer Res; 2014 Mar 01; 20(5):1323-34. PubMed ID: 24443521
    [Abstract] [Full Text] [Related]

  • 12. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
    Sato H, Soh J, Aoe K, Fujimoto N, Tanaka S, Namba K, Torigoe H, Shien K, Yamamoto H, Tomida S, Tao H, Okabe K, Kishimoto T, Toyooka S.
    Int J Oncol; 2019 Jun 01; 54(6):2139-2148. PubMed ID: 30942424
    [Abstract] [Full Text] [Related]

  • 13. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R, Alì G, Giannini R, Proietti A, Lucchi M, Chella A, Melfi F, Mussi A, Fontanini G.
    Oncotarget; 2017 Jan 10; 8(2):2758-2770. PubMed ID: 27835874
    [Abstract] [Full Text] [Related]

  • 14. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S, Viberti C, Cugliari G, Allione A, Casalone E, Betti M, Ferrante D, Aspesi A, Casadio C, Grosso F, Libener R, Piccolini E, Mirabelli D, Dianzani I, Magnani C, Matullo G.
    J Thorac Oncol; 2019 Mar 10; 14(3):527-539. PubMed ID: 30408567
    [Abstract] [Full Text] [Related]

  • 15. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G.
    J Thorac Oncol; 2013 Oct 10; 8(10):1317-28. PubMed ID: 24457242
    [Abstract] [Full Text] [Related]

  • 16. Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.
    Xiao Y, Huang W, Zhang L, Wang H.
    Front Endocrinol (Lausanne); 2022 Oct 10; 13():1056152. PubMed ID: 36523602
    [Abstract] [Full Text] [Related]

  • 17. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M, Trapani D, Ravn J, Sørensen JB, Andersen CB, Grauslund M, Santoni-Rugiu E.
    Anticancer Res; 2015 Nov 10; 35(11):6223-9. PubMed ID: 26504055
    [Abstract] [Full Text] [Related]

  • 18. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E, Giacomino A, Martinetto F, Morone S, Lo Buono N, Ferrero E, Scagliotti G, Novello S, Orecchia S, Ruffini E, Rapa I, Righi L, Volante M, Funaro A.
    Oncotarget; 2014 Aug 15; 5(15):6191-205. PubMed ID: 25026285
    [Abstract] [Full Text] [Related]

  • 19. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L, Tounsi A, Berenguer-Daizé C, Dussault N, Delfino C, Benyahia Z, Cayol M, Mabrouk K, Garcia S, Martin PM, Barlesi F, Ouafik L.
    J Thorac Oncol; 2016 Jan 15; 11(1):94-107. PubMed ID: 26762744
    [Abstract] [Full Text] [Related]

  • 20. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
    Clin Lung Cancer; 2019 Sep 15; 20(5):e564-e575. PubMed ID: 31279641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.